China Meheco(SH:600056) Zhi Tong Cai Jing·2025-09-23 08:18Core Viewpoint - China Pharmaceutical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) received approval from the National Medical Products Administration for the supplement application of Lincomycin Hydrochloride Injection, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Market Impact - Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection is primarily used to treat severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus [1] - The approval of the drug through the consistency evaluation will enhance its market competitiveness and further expand its market share [1] - Drugs that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions according to national policies [1]